Bu광 Pharm’s Latuda earns 7 billion won in first-half sales as company targets depression market

Boryung Pharmaceutical crossed 100 billion won in first-half revenue for the first time since its founding, with its prescription-drug business helping drive the increase.

The company’s total revenue from strategically important prescription medicines rose 7% from the same period a year earlier. Its central nervous system portfolio performed particularly strongly, gaining 32%.

Latuda, the schizophrenia drug launched in 2024, stands at the center of that growth. Boryung is now moving to expand the medicine’s reach into the depression market, adding a new focus to its CNS strategy.

Improved results at subsidiaries also contributed to the company’s performance, but the growth of its core prescription business supported the broader expansion. The drugmaker reported first-half Latuda sales of 7 billion won.